Need to keep on high of the science and politics driving biotech as we speak? Join to get our biotech e-newsletter in your inbox.
Good morning, let’s get straight to the information as we speak.
The necessity-to-know this morning
- Eli Lilly is shopping for Verve Therapeutics, developer of gene-editing therapies for heart problems, for $1 billion plus a CVR probably price one other $300 million.
- Dyne Therapeutics obtained FDA clearance to hunt accelerated approval for its drug to deal with myotonic dystrophy kind 1. Nonetheless, the corporate pushed again the timing of the submission to “late 2026” from its earlier steerage of “first half 2026.”
Duchenne households are fearful and divided after affected person’s dying
Following Sarepta Therapeutics’ disclosure {that a} second boy who took its gene remedy for Duchenne muscular dystrophy has died, the affected person group is offended, fearful, and divided over whether or not to keep up hope within the remedy.
